Gene therapy is no longer an approach for the future. It's a technique used now.
As of January 2020, the FDA has approved four gene therapies for use in the United States and has received more than 900 investigational new drug (IND) applications for clinical studies. At present, more than 3,400 active gene therapy trials are taking place worldwide, according to ClinicalTrials.gov.
None of these trials would have launched without valid preclinical research. One of the key requirements during preclinical research is selection of the appropriate animal model.
Selecting animal models that reflect the population studied and reproduce the target disease state increases the likelihood that studies will meet strict regulatory expectations. Further, strong preclinical research, with accurate data and clinically relevant biomarkers, helps ensure that clinical trials get to the finish line on time and on budget.
"If you choose a too simplistic model or a model that does not accurately recapitulate the disease state you're trying to address, your preclinical data doesn't amount to much,"said Anjli Venkateswaran, PhD, spokesperson for Biomere, a preclinical CRO based in Worcester, Massachusetts. "Selection becomes even more important in gene therapy research, and it's something scientists grapple with daily."
Gene therapy researchers rely on animal models to assess variables such as safety, efficacy, dosage and localization of transgene expression. Traditional inbred and outbred mice the most common laboratory mice are suitable for most pharmaceutical research. However, when the goal is to alter a human genetic defect, scientists need to test their approach in models that contain the human target sequences. This led to the development of genetically engineered mouse models (GEMMs) of which there are many.
"Any mouse that is genetically changed or altered to be an appropriate model for disease falls under this umbrella,"Dr. Venkateswaran said. "These models express the gene target and recapitulate some, if not all, of the disease pathophysiology."
As animal model providers gain access to next-generation sequencing, genome-engineering tools and other technology, they can develop more customized models. "Older technology was based on homologous recombination,"said Tom Pack, PhD, senior scientist for Axovant, a New York City-based clinical-stage gene therapy company. "Now we've moved into an era of CRISPR-Cas9, where you have more efficient and sophisticated technology for manipulating DNA, and you can more closely mimic human mutations. You can also focus on specific organs or tissue types with DNA recombinase-based and intersectional genetics approaches to design more targeted therapies more rapidly."
For all the technological advances, certain studies may require a different type of model. "There are limitations as to how much you can humanize mice,"Dr. Venkateswaran said. "Also, mice behave very differently physiologically from humans, and they have a different blood-brain barrier, which can result in differences in gene therapy delivery to the brain. Because of their anatomical differences, large-animal models are emerging in gene therapy."
Large-animal models, including nonhuman primates, may suit certain studies more specifically than humanized mice. For example, pig models have been used effectively in cystic fibrosis studies because their respiratory is more similar to humans than mouse models.
However, large-animal models have limitations. They are more expensive than mouse models and require specialized scientists and technicians and adequate lab space. That's why Dr. Venkateswaran recommends that, generally, researchers should start small and move up.
"You need to get some confidence in your gene therapy's performance,"she said. "When data looks good in in vitro models and in mouse models, then, depending on the therapy, consider testing in relevant large animal models."
Axovant has two pediatric rare-disease studies in the pipeline: both fatal diseases with no other treatment options available. These delicate situations require Axovant to be especially thoughtful about model selection.
"You not only want to mimic the genetic condition, you want to be able to practice the same surgical techniques you would use to deliver the therapy as well as look at some of the same clinical biomarkers,"Dr. Pack said. "With a larger-animal model, you can optimize everything clinically before you start clinical trials."
To determine the appropriate animal model(s) for preclinical gene therapy studies, researchers must weigh both scientific and practical considerations.
Scientific considerations include:
Practical considerations include:
Gene therapy researchers have a lot to consider when designing preclinical research. Appropriate animal model selection is one of the first and most important steps to help move that research into clinical trials.
Fortunately, a select group of CROs have preclinical research expertise to help expedite the process. That includes access to complex genetically modified mouse models and other animal models, as well as scientific experts that understand the biology of these models. Many CROs, including Biomere, also have housing and breeding programs and experience with testing multiple types of therapies (CRISPR-mediated gene editing, AAV and other viruses, RNA therapeutics (RNAi andmiRNA), ceDNA, antisense oligos etc.).
"When you get it right in preclinical studies, you improve the success rate in the clinic,"Dr. Venkateswaran said. "A more thoughtful approach will lead to more robust therapies, which ultimately leads to more patient lives saved." To learn more about model selection for gene therapy studies, download Biomere's white paper.
Need a preclinical partner for a gene therapy study? Visit Biomere.com to contact one of its scientists about your preclinical study today.
Meyerholz DK. Lessons learned from the cystic fibrosis pig.Theriogenology. 2016;86(1):427-432. doi:10.1016/j.theriogenology.2016.04.057
- Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results - Yahoo Finance - February 27th, 2024
- New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle - CNBC - February 27th, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 27th, 2024
- Former Penn employee sues Gene Therapy Program director, alleging 'unethical and illegal conduct' - The Daily Pennsylvanian - February 27th, 2024
- Gene therapy can't cure deafness because it doesn't need to be cured - The Philadelphia Inquirer - February 27th, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- CU Anschutz Set to Launch Gene Therapy Trials for Heart Disorder - University of Colorado Anschutz Medical Campus - February 27th, 2024
- ICH targets cell and gene therapies, real-world data as topics ripe for harmonization - Regulatory Focus - February 27th, 2024
- Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 - Business Wire - February 27th, 2024
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in ... - GlobeNewswire - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - The Bakersfield Californian - February 27th, 2024
- Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - STAT - February 27th, 2024
- Ed Silverman on new gene therapies, biosimilars, coffee, and more - STAT - STAT - February 27th, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 27th, 2024
- NCDHHS working with federal government on increasing access to sickle cell disease treatment - WECT - February 27th, 2024
- Cell Therapy Weekly: FDA Approves First Cell Therapy For Solid Tumors - RegMedNet - February 27th, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 27th, 2024
- New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com - The Post and Courier - February 27th, 2024
- Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency - Nature.com - February 18th, 2024
- Gene therapy, blood transfusions, stool monitoring: The Sydneysiders trying to escape death - Sydney Morning Herald - February 18th, 2024
- Not too late to repair: gene therapy improves advanced heart failure in animal model - Baylor College of Medicine | BCM - February 18th, 2024
- Direct Administration of CRISPR-Cas9: Tools for Cell and Gene Therapy - Forbes - February 18th, 2024
- Gene therapy's promise seen in its success for AADC deficiency - AADC News - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment - Diagnostic and Interventional Cardiology - February 18th, 2024
- FDA to review expanded use of Sarepta Duchenne gene therapy - Yahoo Finance - February 18th, 2024
- How gene therapy can help treat a rare blood disorder - KUTV 2News - February 18th, 2024
- CRISPR gene therapy Casgevy secures approval in Europe - Pharmaceutical Technology - February 18th, 2024
- FDA Updates for the Week of Feb. 12, 2024: New Approvals, an Extended Review and Goal Dates Set - Managed Healthcare Executive - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure - Business Wire - February 18th, 2024
- Lisa Jarvis: A cure for some kinds of hearing loss? Gene therapies are getting closer - St. Paul Pioneer Press - February 18th, 2024
- Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of ... - Yahoo Finance - February 18th, 2024
- Crispr Therapeutics' Gene Therapy Wins EU Approval - TipRanks.com - TipRanks - February 18th, 2024
- Revolutionizing Gene Therapy: A Novel Technique for In Vivo CAR T Cells - Medriva - February 18th, 2024
- How Stella Vnook is 'infusing innovation' into cell therapies with Likarda's technology - BioPharma-Reporter.com - February 18th, 2024
- Using cancer's 'superpower' to boost T-cell therapies in mice - FierceBiotech - February 18th, 2024
- Parkinson's Disease Patient Identification and Education Will Need to Improve When New Disease Modifying ... - Yahoo Finance - February 18th, 2024
- CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance - February 18th, 2024
- Gene Therapy: A Ray of Hope for Heart Failure Treatment | Health News - Medriva - February 18th, 2024
- Gene therapy trials restore hearing to children born deaf - The Hill - February 2nd, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 2nd, 2024
- Sickle cell gene therapy first focus of Medicaid pay model - Modern Healthcare - February 2nd, 2024
- Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer - BioPharma-Reporter.com - February 2nd, 2024
- Angiodema: Gene therapy blocks painful hereditary disorder - BBC - February 2nd, 2024
- FDA: Genome editing therapies may use accelerated approval pathway - Regulatory Focus - February 2nd, 2024
- CRISPR tech treats severe hereditary condition successfully - Interesting Engineering - February 2nd, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - February 2nd, 2024
- Gene-based therapy may slow development of life-threatening heart condition - Medical Xpress - February 2nd, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 2nd, 2024
- Replacing the PKP2 gene prolongs survival in ARVC patients - Drug Target Review - February 2nd, 2024
- Cell and gene therapies top pharmaceutical industry trend to watch for 2024 - Pharmaceutical Technology - February 2nd, 2024
- Gene Therapy Restores Hearing in Children with Hereditary Deafness - The Hearing Review - February 2nd, 2024
- 2 Dutch among 10 "functionally cured" of hereditary swelling disease by new gene therapy - NL Times - February 2nd, 2024
- FDA publishes final industry guidance for CAR-T and gene therapies - PMLiVE - February 2nd, 2024
- Gene therapy cures hereditary deafness in two people - Advanced Science News - February 2nd, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 2nd, 2024
- Vivet Therapeutics Receive 4.9 Million to Advance Development of Gene Therapy - European Pharmaceutical Manufacturer - February 2nd, 2024
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on ... - GlobeNewswire - February 2nd, 2024
- Allogene parks Notch CARs, leaving one on the road - FierceBiotech - February 2nd, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 25th, 2024
- Gene-therapy breakthrough allows congenitally deaf children to hear Harvard Gazette - Harvard Gazette - January 25th, 2024
- Gene therapies restore hearing in several kids with inherited deafness - Livescience.com - January 25th, 2024
- Boy born deaf can hear for the first time thanks to a gene therapy procedure - NBC 6 South Florida - January 25th, 2024
- Gene therapy restores hearing in children with hereditary deafness - Medical Xpress - January 25th, 2024
- Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss - PR Newswire - January 25th, 2024
- Children's Hospital of Philadelphia uses gene therapy to help 11-year-old boy hear for 1st time - WPVI-TV - January 25th, 2024
- Breakthrough gene therapy treatment restores hearing in children born deaf - The Independent - January 25th, 2024
- Gene Therapy Administered Via Virus Cures Deafness in 11-Year-Old Boy - Futurism - January 25th, 2024
- 11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience - January 25th, 2024
- Gene Therapy Deafness | National | caledonianrecord.com - The Caledonian-Record - January 25th, 2024
- Sickle cell gene therapy to be covered by Blue Cross insurers - Modern Healthcare - January 25th, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - Jackson Hole News&Guide - January 25th, 2024
- Gene therapy allows 11-year-old boy to hear for the first time - Latest From ITV News - ITVX - January 25th, 2024
- Experimental Gene Therapy Allows Kids With Inherited Deafness To Hear - Southern Minnesota News - January 25th, 2024
- Joint US-China gene therapy trials restore hearing in 5 kids, a first - Interesting Engineering - January 25th, 2024
- Gene Therapy Deafness | Nation | The Daily News - Galveston County Daily News - January 25th, 2024
- In Draft Guidance for Cell and Gene Therapy Industry, FDA Broadens its Approach to Product Potency - Precision Medicine Online - January 25th, 2024
- Gene therapy helps restore hearing in children with hereditary deafness - Shropshire Star - January 25th, 2024
- Gene therapy breakthrough enables deaf boy to hear for the first time - The Week - January 25th, 2024
- FDA eyes collaborative review pilot for gene therapies - Regulatory Focus - January 17th, 2024